111 related articles for article (PubMed ID: 12973672)
1. Tissue and serum loss of metalloproteinase inhibitors in high grade soft tissue sarcomas.
Benassi MS; Magagnoli G; Ponticelli F; Pazzaglia L; Zanella L; Gamberi G; Ragazzini P; Ferrari C; Mercuri M; Picci P
Histol Histopathol; 2003 Oct; 18(4):1035-40. PubMed ID: 12973672
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.
Kallakury BV; Karikehalli S; Haholu A; Sheehan CE; Azumi N; Ross JS
Clin Cancer Res; 2001 Oct; 7(10):3113-9. PubMed ID: 11595703
[TBL] [Abstract][Full Text] [Related]
3. Gelatinase and inhibitor expression in soft tissue sarcomas: lack of correlation with distant metastasis.
Maguire PD; Qi W; Lallemand R; Scully SP
Oncology; 2000 Aug; 59(2):139-44. PubMed ID: 10971173
[TBL] [Abstract][Full Text] [Related]
4. Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma.
Kunz P; Sähr H; Lehner B; Fischer C; Seebach E; Fellenberg J
BMC Cancer; 2016 Mar; 16():223. PubMed ID: 26979530
[TBL] [Abstract][Full Text] [Related]
5. Is determination of matrix metalloproteinases and their tissue inhibitors serum concentrations useful in patients with gastroenteropancreatic and bronchopulmonary neuroendocrine neoplasms?
Blicharz-Dorniak J; Kos-Kudła B; Foltyn W; Kajdaniuk D; Marek B; Zemczak A; Strzelczyk J
Endokrynol Pol; 2012; 63(6):470-6. PubMed ID: 23339005
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase expression is related to angiogenesis and histologic grade in spindle cell soft tissue neoplasms of the extremities.
Roebuck MM; Helliwell TR; Chaudhry IH; Kalogrianitis S; Carter S; Kemp GJ; Ritchie DA; Jane MJ; Frostick SP
Am J Clin Pathol; 2005 Mar; 123(3):405-14. PubMed ID: 15716237
[TBL] [Abstract][Full Text] [Related]
7. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
[TBL] [Abstract][Full Text] [Related]
8. MMP/TIMP imbalance in amniotic fluid during PROM: an indirect support for endogenous pathway to membrane rupture.
Fortunato SJ; Menon R; Lombardi SJ
J Perinat Med; 1999; 27(5):362-8. PubMed ID: 10642956
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study.
Pietruszewska W; Bojanowska-Poźniak K; Kobos J
Otolaryngol Pol; 2016 Jun; 70(3):32-43. PubMed ID: 27386931
[TBL] [Abstract][Full Text] [Related]
10. Role of matrix metalloproteinase (MMP) 2 and MMP-9 in soft tissue sarcoma.
Yang HK; Jeong KC; Kim YK; Jung ST
Clin Orthop Surg; 2014 Dec; 6(4):443-54. PubMed ID: 25436070
[TBL] [Abstract][Full Text] [Related]
11. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis.
Kossakowska AE; Edwards DR; Lee SS; Urbanski LS; Stabbler AL; Zhang CL; Phillips BW; Zhang Y; Urbanski SJ
Am J Pathol; 1998 Dec; 153(6):1895-902. PubMed ID: 9846979
[TBL] [Abstract][Full Text] [Related]
12. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
Lorenzl S; Buerger K; Hampel H; Beal MF
Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
[TBL] [Abstract][Full Text] [Related]
13. The Influence of Simvastatin on NGAL, Matrix Metalloproteinases and Their Tissue Inhibitors in Human Intraluminal Thrombus and Abdominal Aortic Aneurysm Tissue.
Piechota-Polanczyk A; Demyanets S; Mittlboeck M; Hofmann M; Domenig CM; Neumayer C; Wojta J; Klinger M; Nanobachvili J; Huk I
Eur J Vasc Endovasc Surg; 2015 May; 49(5):549-55. PubMed ID: 25800096
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
15. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients.
Giannelli G; Erriquez R; Fransvea E; Daniele A; Trerotoli P; Schittulli F; Grano M; Quaranta M; Antonaci S
Int J Cancer; 2004 May; 109(5):782-5. PubMed ID: 14999790
[TBL] [Abstract][Full Text] [Related]
16. Plasma Levels and Tissue Expression of Selected Cytokines, Metalloproteinases and Tissue Inhibitors in Patients With Cervical Cancer.
Sidorkiewicz I; Piskór B; Dąbrowska E; Guzińska-Ustymowicz K; Pryczynicz A; Zbucka-Krętowska M; Ławicki S
Anticancer Res; 2019 Nov; 39(11):6403-6412. PubMed ID: 31704874
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
18. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase expression in high grade soft tissue sarcomas.
Alford SH; Vrana MS; Waite L; Heim-Hall J; Sylvia VL; Williams RP
Oncol Rep; 2007 Dec; 18(6):1529-36. PubMed ID: 17982640
[TBL] [Abstract][Full Text] [Related]
20. High variability in MMP2/TIMP2 and MMP9/TIMP1 expression in secondary liver tumors.
Avădanei R; Căruntu ID; Amălinei C; Lozneanu L; Balan R; Grigoraş A; Ciobanu Apostol D; Giuşcă SE
Rom J Morphol Embryol; 2013; 54(3):479-85. PubMed ID: 24068394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
